Outlook Therapeutics Inc. (NASDAQ:OTLK) saw a downside of -7.66% to close Tuesday at $1.26 after subtracting -$0.11 on the day. The 5-day average trading volume is 2,301,120 shares of the company’s common stock. It has gained $1.5500 in the past week and touched a new high 1 time within the past 5 days. An average of 1,287,115 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 1,361,436.
OTLK’s 1-month performance is -24.70% or -$0.4650 on its low of $1.2100 reached on 08/22/23. The company’s shares have touched a 52-week low of $0.80 and high of $2.03, with the stock’s rally to the 52-week high happening on 06/06/23. YTD, OTLK has achieved 17.13% or $0.1850 and has reached a new high 11 times. However, the current price is down -37.68% from the 52-week high price.
Insider Transactions
OTLK stock investors last saw insider trading activity on Apr 20.Dagnon Terry (Chief Operations Officer) most recently sold 520,000 shares at $1.14 per share on Apr 20. This transaction cost the insider $590,200. Chief Commercial Officer, Evanson Jeff, sold 267,000 shares at a price of $1.11 on Jan 20. Then, on Jan 19, Chief Commercial Officer Evanson Jeff sold 103,255 shares at a price of $1.22 per share. This transaction amounted to $125,971.
Valuation Metrics
OTLK stock has a beta of 0.71. Moving on to other valuation ratios, the price-to-book (PB) in the most recent quarter is 31.62.
Outlook Therapeutics Inc.’s quick ratio for the period ended June 29 was 1.20, with the current ratio over the same period at 1.20.
Earnings Surprise
For the quarterly period ending June 29 this year, Net income and sales went up compared to those figures reported in the previous quarter. Net income grew 15.18% to -$20.68 million, while revenue of -$6.65 million was 67.84% off the previous quarter. Analysts expected OTLK to announce -$0.05 per share in earnings in its latest quarter, but it posted -$0.08, representing a -60.00% surprise. EBITDA for the quarter stood at more than -$18.13 million. OTLK stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 49.95 million, with total debt at $34.74 million. Shareholders hold equity totaling $260.25 million.
Let’s look briefly at Outlook Therapeutics Inc. (OTLK) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 22 August was 24.56% to suggest the stock is trending oversold, with historical volatility in this time period at 79.73%.
The stock’s 5-day moving average is $1.3500, reflecting a -18.39% or -$0.2850 change from its current price. OTLK is currently trading -21.43% above its 20-day SMA, +20.48% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -26.88% and SMA200 by+21.63%.
Stochastic %K and %D was 14.59% and 14.99% and the average true range (ATR) pointed at 0.1045. The RSI (14) points at 29.67%, while the 14-day stochastic is at 11.22% with the period’s ATR at 0.1020. The stock’s 9-day MACD Oscillator is pointing at -0.1317 and -0.2005 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Outlook Therapeutics Inc. (NASDAQ: OTLK), CapitalOne launched coverage with an Overweight rating. Analysts offering their rating for OTLK stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate OTLK as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 1 rates the stock as overweight while 7 have offered a “buy” rating.
What is OTLK’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $4.00 and a high of $10.00, with their median price target at $6.00. Looking at these predictions, the average price target given by analysts is for Outlook Therapeutics Inc. (OTLK) stock is $6.44.
